Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

472

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

January 15, 2031

Study Completion Date

February 15, 2032

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

HEC585

HEC585 tablet, taken once daily

DRUG

Placebo

HEC585 Simulation Board, taken once daily

DRUG

Pirfenidone

Pirfenidone, taken three times a day

All Listed Sponsors

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY